tbuckley/cabot-search huggingface dataset:
P80 A qualitative exploration of the needs and coping strategies of people with severe asthma
Authors: E. J. Humphreys, D. A. Campbell, V. Knowles, E. Wooler, A. Caress
Journal: Thorax (2011)

<h3>Introduction and Objectives</h3> Many people with severe asthma experience frequent debilitating symptoms and treatment side effects, both of which can have a significant impact on their quality of life. While previous qualitative studies have investigated attitudes to healthcare usage among people with severe asthma symptoms, there is relatively little evidence about how people with ongoing severe asthma cope with its broader impact on their lives. This study sought to examine how people with severe asthma and their families view the impact of the condition and how this affects their approach to its management. <h3>Methods</h3> Eight focus groups were held in five tertiary centres around the UK in 2010. Participants were grouped into young people with severe asthma (N=8), adults with severe asthma (N=26) and parents of children with severe asthma (N=17). Discussion guides were initially structured around the revised health belief model (Rosenstock IM, Strecher VJ and Becker MH. Social Learning Theory and the Health Belief Model. <i>Health Educ Behav</i> 1988;<b>15</b>:175–183) which suggests that health behaviours are driven by perceptions in four areas: illness threat, costs and barriers to action, self-efficacy and value of reduced threat. A grounded theory approach was adopted, with concurrent data collection and analysis and adaptations made to the discussion guide in line with emerging themes (Charmaz K. <i>Constructing Grounded Theory</i>. London: Sage, 2006). <h3>Results</h3> Many people felt relatively powerless to improve their ongoing health-related quality of life, because the perceived threats to it posed by their asthma were closely matched by perceived threats of treatment side-effects. Coping strategies to improve quality of life were therefore often targeted at social interactions, rather than improving asthma control. The revised health belief model appeared to be relevant to people affected by severe asthma. <h3>Conclusions</h3> Social support for people with severe asthma may facilitate improved quality of life and interventions that deliver this should be investigated.
THU0125 The Cardiovascular Hazard of NSAIDS in Daily Practice: Prospective Analysis of the ACT-CVD Cohort
Authors: I. Meek, H. Vonkeman, M. van de Laar
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The use of NSAIDs is associated with increased cardiovascular (CV) events and death. The NSAID associated CV hazard of different NSIADs may differ: recently it was found highest in diclofenac, and naproxen was found least harmful.<sup>1</sup> Most studies on NSAID associated CV risk were done in clinical trial populations, which generally are highly selected. <h3>Objectives</h3> to study the cardiovascular (CV) hazard of NSAID treatment in unselected patients, including elderly patients and patients with comorbidities and comedication. <h3>Methods</h3> prospective analysis of 3-year data of the Arthritis Center Twente CardioVascular Disease (ACT-CVD) cohort evaluating the association between continuous use of different non-steroidal anti-inflammatory drugs (NSAIDs; naproxen, diclofenac, ibuprofen, meloxicam or COXIB (etoricoxib or celecoxib)) and the occurrence of first CV events in rheumatoid arthritis (RA) and osteoarthritis (OA). The ACT-CVD cohort contains data of unselected patients with new or longstanding rheumatologic diagnoses, and thus represents a daily clinical rheumatology population. COX-regression analysis was adjusted for baseline estimated 10-year CV risk and intermittent NSAID usage. <h3>Results</h3> Of 686 patients, 46, 37/552 non-NSAID and 9/134 NSAID users, had experienced a first CV event after a median follow up of 36 months. COX regression analysis showed a significant association between baseline continuous use of ibuprofen (HR 3.59, 95%CI 1.08-11.93) or COXIB (HR 4.86, 95%CI 1.47-16.11) and the occurrence of major CV events. <h3>Conclusions</h3> in an unselected population of RA and OA patients the tNSAID ibuprofen and COXIBs were associated with a significant increase in CV event risk after only 3 years follow up. <h3>References</h3> Coxib and traditional NSAID Trialist9s Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5264
Oral abstract presentations &amp; Young Investigators Competition
Authors: A. Leone, I. Aquila, C. Vicinanza, C. Iaconetti, A. Bochicchio, S. Ottolenghi, C. Indolfi, B. Nadal-Ginard, G. M. Ellison, D. Torella, C. Mias, G. Genet, C. Guilbeau-Frugier, A. Pathak, J. M. Senard, C. Gales, A. D. Egorova, P. S. J. Khedoe, M. T. H. Goumans, S. M. Nauli, P. Ten Dijke, R. E. Poelmann, B. P. Hierck, M. Miragoli, M. J. Lab, A. Singh, M. Sikkel, A. Lyon, J. Gorelik, C. Cheung, A. S. Bernardo, M. W. Trotter, R. A. Pedersen, S. Sinha, M. Mioulane, G. Foldes, S. E. Harding, B. Reglin, T. W. Secomb, A. R. Pries, M. Buckingham, F. Lescroart, S. Meilhac, J.-F. Le Garrec, N. Rozmaritsa, T. Christ, E. Wettwer, M. Knaut, U. Ravens, S. Tokar, S. Schobesberger, A. Singh, P. T. Wright, M. Miragoli, A. R. Lyon, M. Sikkel, S. E. Harding, J. Gorelik, A. Van Mil, S. Grundmann, M.-J. Goumans, S. Jaksani, P. A. Doevendans, J. P. Sluijter, A. J. Tijsen, A. S. Amin, J. R. Giudicessi, M. W. Tanck, C. R. Bezzina, E. E. Creemers, A. M. Wilde, M. J. Ackerman, Y. M. Pinto, C. Gedicke-Hornung, V. Behrens-Gawlik, D. Khajetoorians, G. Mearini, S. Reischmann, B. Geertz, T. Voit, P. Dreyfus, T. Eschenhagen, L. Carrier, G. D. Duerr, J. C. Heinemann, D. Wenzel, A. Ghanem, J. C. Alferink, A. Zimmer, B. Lutz, A. Welz, B. K. Fleischmann, O. Dewald, M. Sbroggio', A. Bertero, L. Giuliano, M. Brancaccio, G. Tarone, M. Meiser, M. Kohlhaas, Y. Chen, G. Csordas, G. Dorn, C. Maack, B. Stapel, M. Hoch, A. Haghikia, P. Fischer, C. Maack, D. Hilfiker-Kleiner, B. Schroen, M. Corsten, W. Verhesen, L. De Windt, Y. M. Pinto, S. Zacchigna, T. Thum, P. Carmeliet, A. Papageorgiou, S. Heymans, I. G. Lunde, A. V. Finsen, G. Florholmen, B. Skrbic, H. Kvaloy, H. O. Jarstadmarken, I. Sjaastad, T. Tonnessen, C. R. Carlson, G. Christensen, J. Paavola, S. Schliffke, S. Rossetti, I. Kuo, S. Yuan, Z. Sun, P. Harris, V. Torres, B. Ehrlich, P. Robinson, K. Adams, Y.-H. Zhang, B. Casadei, H. Watkins, C. Redwood, A. N. Seneviratne, J. E. Cole, M. E. Goddard, Z. Mohri, A. J. Cross, R. Krams, C. Monaco, B. R. Everaert, S. J. Van Laere, V. Y. Hoymans, J. P. Timmermans, C. J. Vrints
Journal: Cardiovascular Research (2012)
Reasons for UK doctor’s erasure are withheld on grounds of “confidentiality”
Authors: Clare Dyer
Journal: BMJ (2016)

A doctor named Shajul Islam who qualified in 2012 has been struck off the medical register after an extraordinary hearing, conducted entirely in private with no details published about the misconduct, proved against him.

A doctor with that name and year of qualification was charged with involvement in the abduction of two journalists in Syria but was acquitted after the trial collapsed in 2013 when the prosecution offered no evidence. The Medical Practitioners Tribunal Service would not confirm that the doctor who was ordered to be erased …
Effects of Common Pesticides on Prostaglandin D2 (PGD2) Inhibition in SC5 Mouse Sertoli Cells, Evidence of Binding at the COX-2 Active Site, and Implications for Endocrine Disruption
Authors: Subramaniam Kugathas, Karine Audouze, Sibylle Ermler, Frances Orton, Erika Rosivatz, Martin Scholze, Andreas Kortenkamp
Journal: Environmental Health Perspectives (2015)

Background:There are concerns that diminished prostaglandin action in fetal life could increase the risk of congenital malformations. Many endocrine-disrupting chemicals have been found to suppress prostaglandin synthesis, but to our knowledge, pesticides have never been tested for these effects.Objectives:We assessed the ability of pesticides that are commonly used in the European Union to suppress prostaglandin D2 (PGD2) synthesis.Methods:Changes in PGD2 secretion in juvenile mouse Sertoli cells (SC5 cells) were measured using an ELISA. Coincubation with arachidonic acid (AA) was conducted to determine the site of action in the PGD2 synthetic pathway. Molecular modeling studies were performed to assess whether pesticides identified as PGD2-active could serve as ligands of the cyclooxygenase-2 (COX-2) binding pocket.Results:The pesticides boscalid, chlorpropham, cypermethrin, cyprodinil, fenhexamid, fludioxonil, imazalil (enilconazole), imidacloprid, iprodione, linuron, methiocarb, o-phenylphenol, pirimiphos-methyl, pyrimethanil, and tebuconazole suppressed PGD2 production. Strikingly, some of these substances—o-phenylphenol, cypermethrin, cyprodinil, linuron, and imazalil (enilconazole)—showed potencies (IC50) in the range between 175 and 1,500 nM, similar to those of analgesics intended to block COX enzymes. Supplementation with AA failed to reverse this effect, suggesting that the sites of action of these pesticides are COX enzymes. The molecular modeling studies revealed that the COX-2 binding pocket can accommodate most of the pesticides shown to suppress PGD2 synthesis. Some of these pesticides are also capable of antagonizing the androgen receptor.Conclusions:Chemicals with structural features more varied than previously thought can suppress PGD2 synthesis. Our findings signal a need for in vivo studies to establish the extent of endocrine-disrupting effects that might arise from simultaneous interference with PGD2 signaling and androgen action.Citation:Kugathas S, Audouze K, Ermler S, Orton F, Rosivatz E, Scholze M, Kortenkamp A. 2016. Effects of common pesticides on prostaglandin D2 (PGD2) inhibition in SC5 mouse Sertoli cells, evidence of binding at the COX-2 active site, and implications for endocrine disruption. Environ Health Perspect 124:452–459; http://dx.doi.org/10.1289/ehp.1409544
Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors
Authors: Irene Virgolini, Markus Raderer, Amir Kurtaran, Peter Angelberger, Susanne Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent
Journal: New England Journal of Medicine (1994)

Intestinal adenocarcinomas and various endocrine tumors express large numbers of high-affinity receptors for vasoactive intestinal peptide (VIP). We have evaluated the usefulness of scanning with VIP labeled with iodine-123 for tumor localization in patients with gastrointestinal tumors.Radioiodinated VIP was purified by high-pressure liquid chromatography and administered as a single intravenous bolus injection (300 pmol [1 microgram]). Scanning with radiolabeled VIP was compared with computed tomography and scanning with somatostatin analogues in 79 patients with colorectal cancer, pancreatic carcinoma, gastric cancer, carcinoid tumor, or insulinoma.Visualization of gastrointestinal tumors and metastases was obtained with radiolabeled VIP. Binding of the labeled peptide by primary tumors and metastases was visible shortly after the injection and was still demonstrable at 24 hours. In patients with colorectal adenocarcinomas, primary or recurrent tumors were visualized in 10 of 10, liver metastases in 15 of 18, lung metastases in 2 of 3, and lymph-node metastases in 4 of 4. Primary pancreatic adenocarcinomas were visualized by imaging in 10 of 12 patients, and liver metastases were seen in 7 of 7. Primary or recurrent gastric adenocarcinomas were visualized in 5 of 5 patients, and liver metastases were seen in 2 of 2 patients. VIP scans were positive in 9 of 10 patients with carcinoid tumors and in 4 of 4 patients with insulinomas. Some tumors with positive VIP scans were also visualized with somatostatin analogues (4 of 17 colorectal adenocarcinomas, 8 of 9 carcinoids, and 2 of 2 insulinomas). In vitro binding studies confirmed the presence of VIP receptors on gastrointestinal tumors.Scanning with radiolabeled VIP can visualize intestinal tumors and metastases that express receptors for VIP.
AB0879 Effects of Suprascapular Nerve Blockage on Pain and Functional Status in Adhesive Capsulitis: A Prospective Controlled Trial
Authors: Z. Kılıç, M. Bilgilisoy Filiz, T. Çakır, N.F. Toraman
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Adhesive capsulitis is a common disorder characterized by severe shoulder pain and progressive limitation of active and passive glenohumeral movements (1,2). <h3>Objectives</h3> The aim of this study was to eveluate the effects of suprascapular nerve block (SSNB) combined with physical therapy (PT) on patients9 pain and functional status. <h3>Methods</h3> Forty one patients with adhesive capsulitis were randomly assigned to SSNB group (n:19) and PT alone group (n:22). All patients received 15 sessions PT consisting of ultrasound therapy, superficial heat application, analgesic current and range of motion (ROM) and stretching exercises. The patients in the study group received SSNB with before PT. SSNB was applied with triamsinolone and prilokain at the suprascapular notch. Outcome measures were evaluated three times, before treatment, at the end of the treatment, and after one month of treatment. Pain was assessed by Brief Pain Inventory (BPI), ROM and functional status were assessed by total Constant score. <h3>Results</h3> Both treatment groups improved significantly in all follow-up parameters (p&lt;0.05) except for BPI-9c of PT group (p&gt;0.05). Comparisons of the differences between groups indicated that, 1-2, 1-3. evaluations of BPI-5, 1-2. evaluation of BPI-6, 1-2. evaluation of BPI-9a, 1-2, 1-3. evaluations of BPI-9g were statistically significant in SSNB group (table-1). No complications or drop outs occurred during the trial. <h3>Conclusions</h3> Although better results were achieved in SSNB group, both treatments found to be effective in reducing pain severity and fuctional disability. These findings suggest that suprascapular nerve block is a safe and effective alternative in patients with adhesive capsulitis. <h3>References</h3> Dahan THM, Fortine L,Pelletier M. Double blind randomized clinical trial examining the efficacy of suprascapular nerve block in frozen shoulder. The J Rheumatol. 2000;27:1464-1469 Taşkaynatan MA, Yılmaz B, Özgül A.Yazıcıoğlu K, Kalyon TA.Suprascapular nerve block versus steroid injection for non-spesific shoulder pain. Tohoku J. Exp.Med. 2005;205:19-25 <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2278
Case 39-2003
Authors: Niall M. Heney, Robert H. Young
Journal: New England Journal of Medicine (2003)

Presentation of CaseA 33-year-old woman was admitted to the hospital because of gross hematuria.The patient had been in stable health until four days earlier, when gross hematuria developed, with passage of clots and mild dysuria but without an increase in urinary frequency. She came to this hospital, where a urine specimen was obtained for culture and where a presumed urinary tract infection was treated with trimethoprim–sulfamethoxazole; she also was referred to a urologist. The hematuria and clots persisted and worsened two days before admission. One day before admission, the urine culture yielded a few mixed bacteria. An attempted . . .
RT-40 * THE DOWN-REGULATION OF H-FERRITIN AS AN ADJUVANT THERAPY IN HUMAN GLIOMA
Authors: M. Pang, X. Liu, A. B. Madhankumar, B. Slagle-Webb, J. Connor
Journal: Neuro-Oncology (2014)

Cancer cells generally exhibit increased iron requirements and heightened iron metabolism. As the major iron storage protein, ferritin expression is elevated in many types of cancer. In this study, we report that the sensitization of H-ferritin down-regulation in glioma cells against radiation and suggest the potential of H-ferritin down-regulation as an adjuvant therapy in human glioma. In human glioma cells, down-regulation of H-ferritin performed through a nanotechnology-based transfection platform led to a transient decrease in transferrin receptor level, suggesting a release of intracellular iron with loss of ferritin. This iron release in turn produced intracellular oxidative stress, demonstrated by protein oxidation damage, as well as a decrease in the stability of hypoxia-inducible factors (HIFs), which is an indicator of radioresistance. In glioma cells, exposure to radiation resulted in protein oxidation which could be exacerbated by H-ferritin down-regulation. Previously we have demonstrated a DNA protection role for H-ferritin. Here we expand this concept by showing that the down-regulation of H-ferritin is associated with increased DNA vulnerability when cells were exposed to ionizing radiation. The activation of DNA repair mechanisms was impaired when H-ferritin was absent. The in vitro data suggest a synergistic effect of radiation and H-ferritin down-regulation. Additionally, we expand our research into CD133-positive glioma stem cells (GSCs), which are notoriously resistant to anti-cancer treatment. Down-regulation of H-ferritin in GSCs inhibited cell proliferation in vitro, presumably through apoptosis induction. With an intracranial glioma model established by GSC implantation, we demonstrated that the survival was significantly prolonged by H-ferritin siRNA transfection through intravenous injection, in tumor bearing mice treated with first-line drug Temodar. This study supports the potential of H-ferritin siRNA as an adjuvant therapy in glioma treatment.
Case 23-2011 — Legal Considerations
Authors: Joshua L. Abrams, Jeffrey L. Ecker, William H. Barth
Journal: New England Journal of Medicine (2011)

To the Editor: Having received comments regarding the legal issues raised in our article about a pregnant woman with placenta accreta who declined blood products (July 28 issue),1 we wish to acknowledge that that the legal issues that were discussed are decided on a state-by-state basis and that the legal analysis presented was based on Massachusetts law. As in the case of Norwood Hospital v. Munoz that we cited, a determination was made in this case that forced blood transfusion would not be appropriate owing to the existence of a legal caregiver (the husband) for the children. Whether a particular . . .
S95 SOCCAR: Internationally Resonant Results from a Randomised Trial Based on UK Clinical Practise
Authors: J Maguire, N O’Rourke, R McNememin, C Peedell, M Snee, V Kelly, I Khan
Journal: Thorax (2012)

Concurrent chemoradiation is now recognised as a standard of care for patients with inoperable Stage III NSCLC and good Performance Status. Two year survival rates in published trials ranges from 29% to 43%, with median survival in the range of 14 to 17 months. An ongoing multi-centre study performed in the United States has recently reported median survival of 21 months for this group of patients, with no advantage from dose escalation from 60 to 74 Gy in conventional fractionation. In SOCCAR, we employed a standard UK radical lung cancer radiotherapy treatment schedule; 130 patients were randomised to receive 55Gy in 20 fractions over 4 weeks, given either concurrently or sequentially with cisplatinum and vinorelbine. Trial entry criteria were: pathologically confirmed stage III NSCLC, judged in-operable by a thoracic surgeon and treatable within a radical radiotherapy volume with V20 &lt;30% and &lt;12 cm oesophagus in PTV. Patients were required to have PS 0 or 1, FEV1 &gt;/= 1L and TLCO &gt;/= to 50%. Patients with weight loss and N3 disease were included, with no upper age limit. Characteristics were well balanced between the two arms. <h3>Results</h3> Median survival is 27.4 months in the concurrent arm and 18.6 months in the sequential arm. Two year survival rates are 54% and 42% respectively. Toxicity was acceptable and similar in both arms. Documented local relapse was 10% in the concurrent arm and 22% in the sequential arm. Quality of Life was measured prospectivly in all patients, there being no significant difference in either arm. In comparison with 16 published RCTs, comprising 1733 patients treated with concurrent chemoradiation, the concurrent treatment arm in SOCCAR ranks top in survival with comparable toxicity. These results are recognised as being of major relevance internationally and are the basis of a proposed multi-centre international study.
Determinant Role of Tc-99m MIBI SPECT in the Localization of a Retrotracheal Parathyroid Adenoma Successfully Treated by Radioguided Surgery
Authors: Domenico Rubello, Dario Casara, Costantino Pagetta, Andrea Piotto, Maria Rosa Pelizzo, Brahm Shapiro
Journal: Clinical Nuclear Medicine (2002)

Purpose The authors’ aim was to evaluate the role of MIBI SPECT acquired just after planar pertechnetate-MIBI (TcO4–MIBI) subtraction scintigraphy in planning radioguided surgery in a patient with persistent primary hyperparathyroidism after initial surgery performed to treat a retrotracheal parathyroid adenoma (PA). Methods A 73-year-old man with persistent primary hyperparathyroidism after a previous left parathyroidectomy and left thyroid lobectomy is described. The patient was examined in our center in a single-day preoperative imaging protocol based on findings of planar TcO4–MIBI subtraction scintigraphy, MIBI SPECT, high-resolution neck ultrasound, and computed tomography. Results Neck ultrasound did not reveal enlarged parathyroid glands. Findings of a neck–chest computed tomographic scan were also inconclusive. Instead, planar scintigraphy clearly depicted a single focus of MIBI uptake over the thyroid gland in a median position. The SPECT examination precisely localized a PA in the retrotracheal space. The day after imaging, the patient underwent unilateral left cervical surgical exploration. A 16 × 21 mm PA was easily detected using the gamma probe technique after injection of a low dose of 37 MBq (1 mCi) Tc-99m MIBI, and the PA was rapidly removed with limited surgical trauma. Rapid serum PTH and calcium levels normalized after intervention and remained in the normal range during subsequent follow-up. Conclusions The current data indicate the importance of preoperative imaging with MIBI scintigraphy in patients with primary hyperparathyroidism and strongly support the utility of MIBI SPECT acquisition in PAs located deep in the neck and in ectopic sites. Furthermore, the gamma probe can help the surgeon to detect the PA during surgery and to minimize the surgical trauma in patients who have had previous thyroid or parathyroid surgery.
Book: Terminal Consent
Authors: J. C Roberts
Journal: BMJ (1999)

Michael Freeny William Austin Press, £9.14, pp 371 ISBN 0 9663686 6 5 Rating:![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> When George Orwell wrote 1984 in 1949 the free world had just destroyed two totalitarian regimes and still faced another. The idea of Big Brother was all too real, even though the technology that Orwell described was not. Michael Freeny, an American psychologist, has written a novel somewhat like 1984 , but this time the technology is all too real, and the threat comes not from a political regime but from the marketplace. The reality of modern information technology makes this book terrifying. When we pay our bills or use our credit cards, banking machines, … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
1303 PREVALENCE OF HEPATIC STEATOSIS AND ITS RELATIONSHIP WITH CARDIOVASCULAR RISK IN HIV-PATIENTS WITH OR WITHOUT HCV CO-INFECTION
Authors: V. Li Vecchi, M. Soresi, L. Giannitrapani, P. Di Carlo, G. Mazzola, P. Colletti, A. Terranova, G. Montalto
Journal: Journal of Hepatology (2012)